Compare MPLT & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPLT | SGP |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 811.3M | 932.9M |
| IPO Year | N/A | N/A |
| Metric | MPLT | SGP |
|---|---|---|
| Price | $24.19 | $22.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $32.67 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 194.6K | 107.6K |
| Earning Date | 05-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.24 | $20.15 |
| 52 Week High | $24.15 | $30.56 |
| Indicator | MPLT | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 75.09 | 38.08 |
| Support Level | $16.19 | $21.29 |
| Resistance Level | N/A | $28.17 |
| Average True Range (ATR) | 1.56 | 2.16 |
| MACD | 0.64 | -0.36 |
| Stochastic Oscillator | 83.57 | 21.91 |
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.